Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback